Crestline Management’s Peak Bio, Inc. Common Stock PKBO Stock Holding History

Crestline Management’s Portfolio PKBO Stock Details PKBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-45,724	Closed	-$457K	–	247
2022 Q3	$457K	Hold	45,724	–	–	0.06%	154
2022 Q2	$451K	Hold	45,724	–	–	0.06%	174
2022 Q1	$449K	Buy	45,724 +24,800	+119%	+$243K	0.05%	189
2021 Q4	$204K	Hold	20,924	–	–	0.02%	195
2021 Q3	$205K	Hold	20,924	–	–	0.02%	202
2021 Q2	$203K	Buy	+20,924	New	+$204K	0.02%	161

Other funds holding PKBO

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Crestline Management's PKBO Position: Q4 2022 in Review

Crestline Management sold out of Peak Bio, Inc. Common Stock (PKBO) in Q4 2022, closing a stake of 45,724 shares — an estimated $457K sold.

Crestline Management first reported a position in PKBO in Q2 2021 and held it in 6 quarters. The position peaked at $457K in Q3 2022. 9 funds tracked by Wall St. Rank hold PKBO as of Q4 2022.

Crestline Management reported no remaining Peak Bio, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Crestline Management sold 45,724 Peak Bio, Inc. Common Stock shares in Q4 2022, an estimated $457K.
Crestline Management first reported a position in Peak Bio, Inc. Common Stock in Q2 2021 and held it in 6 quarters.
Crestline Management's Peak Bio, Inc. Common Stock position peaked at $457K in Q3 2022.
9 funds tracked by Wall St. Rank held Peak Bio, Inc. Common Stock as of Q4 2022.

Based on Crestline Management's 13F filing for Q4 2022, filed 13 Feb 2023.